The variability in the clinical effects of indolcarbinol in women with mastodynia
Vorontsova A.V., Zvychayny M.A., Guzhavina P.A.
Objective: To present the experience of using indolcarbinol in patients with fibrocystic mastopathy.
Materials and methods: These are the results of monitoring the use of indolcarbinol for 6 months in 81 women aged 40–45 years with cyclic mastodynia accompanied by diffuse fibrocystic mastopathy (DFCM).
Results: The use of indolcarbinol for 6 months in women with cyclic mastodynia does not have a negative effect on the nature of the menstrual cycle. Its use is also accompanied by such positive trends as improvement of menstrual function, a significant decrease in the severity of dysmenorrhea as well as control of premenstrual syndrome, improvement of some ultrasound parameters characterizing adenomyosis. There is also a complete control of mastodynia, reduction or disappearance of edema and heterogeneity of the structure of the mammary glands during palpation and positive changes according to ultrasound of the mammary glands (restoration of the average echogenicity of the tissue, decrease in the diameter of the milk ducts and cysts, normalization of the severity of the connective tissue pattern, etc.).
Conclusion: The results of the observation confirmed the effectiveness and safety of indolcarbinol in women with cyclic mastodynia, which is accompanied by different variants of DFCM, both isolated and combined with uterine fibroids and adenomyosis, which can often be found in this cohort of patients.
Authors' contributions: Vorontsova A.V., Zvychayny M.A., Guzhavina P.A. – developing the design of the study, obtaining data for analysis, reviewing publications on the topic of the article, statistical analysis of the data obtained, writing the text of the article.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
Ethical Approval: The study was approved by the Ethical Review Board of the Ural State Medical University, Ministry of Health of Russia.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Vorontsova A.V., Zvychayny M.A., Guzhavina P.A.
The variability in the clinical effects of indolcarbinol in women with mastodynia.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (5): 144-151 (in Russian)
https://dx.doi.org/10.18565/aig. 2024.113
Keywords
mastodynia
indolcarbinol
premenstrual syndrome
adenomyosis
uterine fibroids
References
- Лещенко О.Я. Мастодиния. Современные данные о причинах, течении, диагностике и подходах к коррекции. Гинекология. 2023; 25(3): 282-9. [Leshchenko O.Ya. Mastodynia: Current data on the causes, course, diagnosis, and treatment approaches. A review. Gynecology. 2023; 25(3): 282-9. (in Russian)]. https://dx.doi.org/10.26442/20795696.2023.3.202341.
- Пушкарев А.В., Галеев М.Г., Пушкарев В.А., Турсуметов Д.С., Мухаметдинов М.Р. Доброкачественные опухоли молочной железы и факторы риска их развития. Уральский медицинский журнал. 2022; 21(5): 128-37. [Pushkarev A.V., Galeev M.G., Pushkarev V.A., Tursumetov D.S., Mukhametdinov M.R. Benign breast tumors and risk factors for their development. Ural Medical Journal. 2022; 21(5): 128-37. (in Russian)]. https://dx.doi.org/10.52420/2071-5943-2022-21-5-128-137.
- Каприн А.Д., Рожкова Н.И., ред. Доброкачественные заболевания молочной железы. М.: ГЭОТАР-Медиа; 2019. 272 с. [Kaprin A.D., Rozhkova N.I., ed. Benign breast diseases. Moscow: GEOTAR-Media; 2019. 272 p. (in Russian)].
- Lamceva J., Uljanovs R., Strumfa I. The main theories on the pathogenesis of endometriosis. Int. J. Mol. Sci. 2023; 24(5): 4254. https://dx.doi.org/10.3390/ijms24054254.
- Bulun S.E., Yildiz S., Adli M., Chakravarti D., Parker J.B., Milad M. et al. Endometriosis and adenomyosis: shared pathophysiology. Fertil. Steril. 2023; 119(5): 746-50. https://dx.doi.org/10.1016/j.fertnstert.2023.03.006.
- Yang Q., Ciebiera M., Bariani M.V., Ali M., Elkafas H., Boyer T.G. et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr. Rev. 2022; 43(4): 678-719. https://dx.doi.org/10.1210/endrev/bnab039.
- Driva T.S., Schatz C., Sobočan M., Haybaeck J. The role of mTOR and eIF signaling in benign endometrial diseases. Int. J. Mol. Sci. 2022; 23(7): 3416. https://dx.doi.org/10.3390/ijms23073416.
- Nees L.K., Heublein S., Steinmacher S., Juhasz-Böss I., Brucker S., Tempfer C.B. et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch. Gynecol. Obstet. 2022; 306(2): 407-21. https://dx.doi.org/10.1007/s00404-021-06380-5.
- Schnekenburger M., Diederich M. Chapter 18 - Nutritional epigenetic regulators in the field of cancer: New avenues for chemopreventive approaches. In: Gray S.G., ed. Epigenetic Cancer Therapy. Academic Press; 2015: 393-425. https://dx.doi.org/10.1016/B978-0-12-800206-3.00018-5.
- Centofanti F., Buono A., Verboni M., Tomino C., Lucarini S., Duranti A. et al. Synthetic methodologies and therapeutic potential of Indole-3-Carbinol (I3C) and its derivatives. Pharmaceuticals (Basel). 2023; 16(2): 240. https://dx.doi.org/10.3390/ph16020240.
- Baez-Gonzalez A.S., Carrazco-Carrillo J.A., Figueroa-Gonzalez G., Quintas-Granados L.I., Padilla-Benavides T., Reyes-Hernandez O.D. Functional effect of indole-3 carbinol in the viability and invasive properties of cultured cancer cells. Biochem. Biophys. Rep. 2023; 35: 101492. https://dx.doi.org/10.1016/j.bbrep.2023.101492.
- Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al.; STRAW+10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging. J. Clin. Endocrinol. Metab. 2012; 97(4): 1159-68. https://dx.doi.org/10.1210/jc.2011-3362.
- Рожкова Н.И. Рентгенодиагностика заболеваний молочной железы. М.: Медицина; 1993. 222с. [Rozhkova N.I. X-ray diagnosis of breast diseases. Moscow: Medicine; 1993. 222p. (in Russian)].
- Munro M.G., Critchley H.O., Broder M.S., Fraser I.S.; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int. J. Gynaecol. Obstet. 2011; 113(1): 3-13. https://dx.doi.org/10.1016/j.ijgo.2010.11.011.
- Bazot M., Daraï E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. Fertil. Steril. 2018; 109(3): 389-97. https://dx.doi.org/10.1016/j.fertnstert.2018.01.024.
- Munro M.G., Critcheley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int. J. Gynaecol. Obstet. 2018; 143(3):393-408. https://dx.doi.org/10.1002/ijqo.12666.
- Harmsen M.J., Van den Bosch T., de Leeuw R.A., Dueholm M., Exacoustos C., Valentin L. et al. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: Results of modified Delphi procedure. Ultrasound Obstet. Gynecol. 2022; 60(1): 118-31. https://dx.doi.org/10.1002/uog.24786.
- Вишневский А.С. Гиперпластический синдром в гинекологии. М.: ГЭОТАР-Медиа; 2018. 192 с. [Vishnevsky A.S. Hyperplastic syndrome in gynecology. M.: GEOTAR-Media; 2018. 192 p. (in Russian)].
- Регистрационное удостоверение лекарственного препарата «Индинол Форто». Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c5d8acde-848a-4b2c-a51c-eb9d43b5d8a8. [Registration certificate of the medicinal product "Indinol Forto". Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c5d8acde-848a-4b2c-a51c-eb9d43b5d8a8. (in Russian)].
- Киселев В.И., Сметник В.П., Сутурина Л.В., Селиванов С.П., Рудакова Е.Б., Рахматуллина И.Р., Андреева Е.Н., Фадеева Н.И., Хасанов Р.Ш., Кулагина Н.В., Рожкова Н.И., Артымук Н.В., Гависова А.А., Муйжнек Е.Л., Кузнецов И.Н., Друх В.М. Индолкарбинол (Индинол Форто) – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013; 7: 56-62. [Kiselev V.I., Smetnik V.P., Suturina L.V., Selivanov S.P., Rudakova E.B., Rakhmatullina I.R., Andreyeva E.N., Fadeyeva N.I., Khasanov R.Sh., Kulagina N.V., Rozhkova N.I., Artymuk N.V., Gavisova A.A., Muizhnek E.L., Kuznetsov I.N., Drukh V.M. Indole carbinol (Indinol Forto) is a multitargeted therapy option for cyclic mastodynia. Obstetrics and Gynecology. 2013; (7): 56-62. (in Russian)].
- Боровиков И.О., Куценко И.И., Булгакова В.П., Боровикова О.И. Негормональная терапия пациенток с фиброзно-кистозной мастопатией в сочетании с гиперплазией эндометрия. Медицинский совет. 2021; (21-1): 182-9. [Borovikov I.O., Kutsenko I.I., Bulgakova V.P., Borovikova O.I. Non-hormonal therapy of patients with fibrocystic mastopathy in combination with endometrial hyperplasia. Medical Council. 2021; (21-1): 182-9. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2021-21-1-182-189.
- Ашрафян Л.А., Рожкова Н.И., Прокопенко С.П., Меских Е.В., Артымук Н.В., Белоцерковцева Л.Д., Долгушина В.Ф., Коротких Н.В., Кузнецова Л.В., Кукарская И.И., Кононенко Т.С., Марочко Т.Ю., Соколов К.А., Вербицкая Ю.С. Влияние препарата индолкарбинола на течение циклической масталгии на фоне доброкачественной дисплазии молочной железы в условиях рутинной клинической практики (исследование «АФРОДИТА»). Акушерство и гинекология. 2024; 2: 134-42. [Ashrafyan L.A., Rozhkova N.I., Prokopenko S.P., Meskikh E.V., Artymuk N.V., Belotserkovtseva L.D., Dolgushina V.F., Korotkikh N.V., Kuznetsova L.V., Kukarskaya I.I., Kononenko T.S., Marochko T.Yu., Sokolov K.A., Verbitskaya Yu.S. The effect of the indolcarbinol on cyclic mastalgia in benign mammary dysplasia in routine clinical practice (“APHRODITE” study). Obstetrics and Gynecology. 2024; (2): 134-142 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.35.
Received 02.05.2024
Accepted 24.05.2024
About the Authors
Anna V. Vorontsova, obstetrician-gynecologist, PhD, Associate Professor, Associate Professor of the Department of Obstetrics and Gynecology with a course in medical genetics, USMU, Ministry of Health of Russia, 620028, Russia, Yekaterinburg, Repina str., 3, +7(343) 240-02-91, a_valerevna@mail.ru, Scopus Author ID: 57200595728,SPIN code: 1556-6528, https://orcid.org/0000-0002-0509-3328
Maxim A. Zvychayny, obstetrician-gynecologist, Dr. Med. Sci., Professor, Professor of the Department of Obstetrics and Gynecology with a course in medical genetics, USMU, Ministry of Health of Russia, 620028, Russia, Yekaterinburg, Repina str., 3, +7(343)240-02-91, maksim.zvychainyi@mail.ru, Scopus Author ID: 57222111890,
SPIN code: 7879-6711, https://orcid.org/0000-0003-4728-9553
Polina A. Guzhavina, resident obstetrician-gynecologist of the Department of Obstetrics and Gynecology with a course in medical genetics, USMU, Ministry of Health of Russia, 620028, Russia, Yekaterinburg, Repina str., 3, +7(343)240-02-91, polina_ryabkova@list.ru
Similar Articles
